29.04.2015 • NewsDede WillamsMillikenSilane

SiVance Opens Lab for Silane and Silicone Technologies

Belgium's SiVance, a subsidiary of Milliken & Company, has opened a new research and development laboratory at its R&D and manufacturing campus in Gainesville, Florida.

SiVance said the new center, part of a planned series of investments targeting current and future customer needs in markets such as electronic semiconductors, contact lenses, coatings and light-emitting diodes (LEDs) will enhance its ability to quickly develop and scale new silane and silicone technologies.

The lab is also planned to speed process development for custom manufacturing of specialty silanes, silicones and other chemistries.

"This state-of-the-art facility is a major milestone in our continuous investment strategy for the business, which was initiated following Milliken's acquisition of SiVance in 2011," said SiVance vice president, Saikat Joardar.

Joardar said the new lab will accelerate product and process development and scale up to manufacturing, strengthen collaboration with customers while taking advantage of new market opportunities for chemistries that fit the company's expertise and capabilities.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.